Tags : Risk

Merck and Bayer Receive the US FDA’s Priority Review for

Tuba Khan July 16, 2020

Shots: The NDA is based on P-III VICTORIA study assessing vericiguat (qd, (titrated up to 10mg) vs PBO when given in combination with available HF therapies in ~5,050 patients with […]Read More

Roche’s cobas HPV Test Receives the US FDA’s Approval for

Tuba Khan April 21, 2020

Shots: The US FDA approved Roche’s cobas HPV test for use on cobas 6800/8800 systems that enable molecular laboratories to achieve the efficiency and scale needed for meeting the demands […]Read More

Amgen’s Corlanor (ivabradine) Receives FDA’s Approval to Reduce Risk of

Shiwani Sharma April 15, 2019

Shots: The approval is based on P-III SHIFT study trial assessing Corlanor vs PBO +SoC in 6500+ patients with reduced left ventricular function (LVEF ≤35%) and heart rate ≥70 bpm, […]Read More

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Takeda to Divest TachoSil to Corza Health for ~$416M

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Tags : Risk

Merck and Bayer Receive the US FDA’s Priority Review for

Roche’s cobas HPV Test Receives the US FDA’s Approval for

Amgen’s Corlanor (ivabradine) Receives FDA’s Approval to Reduce Risk of

Latest Posts

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Tags : Risk

Latest Posts

Categories

Related Topics